These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16340485)

  • 21. Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study.
    Tavel JA; ; Babiker A; Fox L; Gey D; Lopardo G; Markowitz N; Paton N; Wentworth D; Wyman N
    PLoS One; 2010 Feb; 5(2):e9334. PubMed ID: 20186278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Introduction. Usefulness of atazanavir in the treatment of patients infected by human immunodeficiency virus].
    Rivero A
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():1. PubMed ID: 20116609
    [No Abstract]   [Full Text] [Related]  

  • 23. Drug profile: fosamprenavir (Lexiva).
    Pham PA
    Hopkins HIV Rep; 2003 Nov; 15(6):10-1. PubMed ID: 14974426
    [No Abstract]   [Full Text] [Related]  

  • 24. Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection.
    Chapman TM; Plosker GL; Perry CM
    Drugs; 2004; 64(18):2101-24. PubMed ID: 15341507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. When and how to use tipranavir and darunavir.
    Hoffman CJ; Gallant JE
    AIDS Read; 2007 Apr; 17(4):194-8, 201. PubMed ID: 17479503
    [No Abstract]   [Full Text] [Related]  

  • 26. [Plasma levels following the switch from amprenavir to fosamprenavir in HIV-infected patients under antiretroviral treatment with lopinavir/ritonavir].
    Delgado O; Riera M; Murillas J; Ventayol P
    Enferm Infecc Microbiol Clin; 2008 Mar; 26(3):182-3. PubMed ID: 18358222
    [No Abstract]   [Full Text] [Related]  

  • 27. Early virologic rebound in a pilot trial of ritonavir-boosted atanazavir as maintenance monotherapy.
    Arribas JR; Pulido F
    J Acquir Immune Defic Syndr; 2007 Sep; 46(1):118; author reply 118-9. PubMed ID: 17909317
    [No Abstract]   [Full Text] [Related]  

  • 28. Proton pump inhibitor therapy in atazanavir-treated patients: contraindicated?
    Furtek KJ; Crum NF; Olson PE; Wallace MR
    J Acquir Immune Defic Syndr; 2006 Mar; 41(3):394-6. PubMed ID: 16540945
    [No Abstract]   [Full Text] [Related]  

  • 29. Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring.
    Slish J; Ma Q; Zingman BS; Reichman RC; Fischl MA; Gripshover B; Forrest A; Brazeau D; Boston NS; Catanzaro L; DiFrancesco R; Morse GD
    Ther Drug Monit; 2007 Oct; 29(5):560-5. PubMed ID: 17898644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: Part II.
    Preskorn SH; Borges-Gonzalez S; Flockhart D
    J Psychiatr Pract; 2006 Sep; 12(5):312-6. PubMed ID: 16998419
    [No Abstract]   [Full Text] [Related]  

  • 31. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy.
    Winston A; Bloch M; Carr A; Amin J; Mallon PW; Ray J; Marriott D; Cooper DA; Emery S
    J Antimicrob Chemother; 2005 Aug; 56(2):380-7. PubMed ID: 15996972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atazanavir gets FDA Advisory Committee's thumbs-up.
    IAPAC Mon; 2003 Jun; 9(6):120. PubMed ID: 12951939
    [No Abstract]   [Full Text] [Related]  

  • 33. [Safety of atazanavir in patients with HIV and hepatitis B and/or C virus coinfection].
    Rivero A; Camacho A; Pérez-Camacho I; Torre-Cisneros J
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():45-8. PubMed ID: 20116617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atazanavir and chest pain.
    Phillips M; Saxon C; Lee V
    Int J STD AIDS; 2014 May; 25(6):461-4. PubMed ID: 24108452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection.
    Kiser JJ; Lichtenstein KA; Anderson PL; Fletcher CV
    Pharmacotherapy; 2006 Apr; 26(4):511-4. PubMed ID: 16553510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Human immunodeficiency virus and Chagas disease coinfection treated successfully with benznidazole and a raltegravir-based antiretroviral regimen: a case report].
    Rodríguez-Guardado A; Tuset M; Asensi V; Miró JM
    Med Clin (Barc); 2011 Sep; 137(6):278-9. PubMed ID: 20980024
    [No Abstract]   [Full Text] [Related]  

  • 37. A single centre cohort experience with a new once daily antiretroviral drug.
    Stebbing J; Bower M; Holmes P; Gazzard B; Nelson M
    Postgrad Med J; 2006 May; 82(967):343-6. PubMed ID: 16679474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine.
    Squires KE; Young B; DeJesus E; Bellos N; Murphy D; Ward D; Zhao HH; Ross LL; Shaefer MS;
    HIV Clin Trials; 2012; 13(5):233-44. PubMed ID: 23134624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Efficacy of atazanavir in simplification regimens].
    Zamora L; Gatell JM
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():14-21. PubMed ID: 20116612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lexiva: blood levels not lowered when taken simultaneously with Nexium.
    James JS
    AIDS Treat News; 2005 May; (412):5. PubMed ID: 16047410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.